在干细胞移植和细胞疗法中肺免疫损害
Mahnoor Mir1, Saadia Faiz2, Anuradha G Bommakanti1
1Divisions of Critical Care, Pulmonary and Sleep Medicine, McGovern Medical School at UTHealth, Houston, TX 77030, USA; Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
肺部并发症,无论是传染性还是非传染性,在输血细胞移植 (HCT) 和仿真抗原受体T细胞 (CAR-T) 疗法后都是显著的风险. 这篇评论详细介绍了这些肺部问题,其原因和诊断策略.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
- 肺部病理学 肺部病理学
背景情况:
- 血造细胞移植 (HCT) 和仿真抗原受体T细胞 (CAR-T) 疗法为血液恶性病和一些非恶性疾病提供了潜在的治疗方法.
- 肺部并发症包括传染性和非传染性原因,是接受这些细胞治疗的患者发病和死亡的主要原因.
研究的目的:
- 为提供与HCT和CAR-T疗法相关的肺部并发症的全面概述.
- 阐明免疫性损害导致感染风险增加的机制.
- 突出可能模仿急性感染的非传染性肺部并发症,并建议诊断和预防策略.
主要方法:
- 这是一个复习文章.
- 它综合了目前关于HCT和CAR-T接受者的肺部并发症的知识.
- 它讨论了潜在的机制,临床表现和诊断方法.
主要成果:
- 在HCT和CAR-T之后的免疫性损害显著增加了肺部感染的风险.
- 非传染性肺部并发症很常见,可能与感染类似,使诊断复杂化.
- 迅速区分传染性和非传染性病因对于有效管理至关重要.
结论:
- 肺部并发症是HCT和CAR-T治疗中的关键问题,影响患者的治疗结果.
- 了解免疫损害,感染和非传染性肺损伤之间的相互作用是必不可少的.
- 有效的诊断和预防策略是必要的,以减轻与这些先进治疗相关的风险.
更多相关视频
09:45Generation of 3D Whole Lung Organoids from Induced Pluripotent Stem Cells for Modeling Lung Developmental Biology and Disease
Published on: April 12, 2021
08:52Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
Published on: May 27, 2011
相关概念视频
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Immunodeficiency Diseases
There are three main causes of immunodeficiency...
Regulation of Hematopoietic Stem Cells
Cell-mediated Immune Responses
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
